SEC Form 4 · accession 0001127602-16-044957

ARIAD PHARMACEUTICALS INC · ARIA

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Officer — President, R&D, CSO

Period of report

Mar 1, 2016

Accepted (ET)

Mar 3, 2016 · 8:00 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000884731

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I
Common Stock	Mar 1, 2016	M	19,250	$0.00	A	369,302	D
Common Stock	Mar 2, 2016	S	25,047	$6.00	D	344,255	D
Common Stock^F3	Mar 3, 2016	S	9,625	$6.1161	D	334,630	D

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Performance stock unit^F4,F5	—	Mar 1, 2016	M	19,250	D	—	—	Common Stock	19,250	19,250	D
Performance stock unit^F4,F5	—	Mar 1, 2016	A	38,500	A	—	—	Common Stock	38,500	38,500	D

F1Shares were acquired upon vesting of performance stock units awarded on January 31, 2014.
F2Represents shares sold to satisfy withholding tax requirements, pursuant to a Rule 10b5-1 trading plan.
F3The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.04 to $6.19, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Security and Exchange Commission, upon request, full information regarding the shares sold at each separate price within the range set forth in this footnote.
F4Each performance stock unit represents a right to receive one share of ARIAD common stock.
F5The performance stock units vest as to 50% of the award on 3/1/2016 and 50% of the award on 3/1/2017.